Phyton Biotech has received Regulatory Approval from China’s NMPA for its plant cell fermentation-derived Paclitaxel Active Pharmaceutical Ingredient.

By |2021-05-26T17:47:45+00:00May 25th, 2021|

Phyton Biotech is pleased to announce approval from China’s regulatory body – National Medical Products Administration (NMPA) - for Phyton’s Drug Master File for paclitaxel active pharmaceutical ingredient produced via plant cell fermentation (PCF®).

Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions

By |2021-01-11T19:00:00+00:00January 11th, 2021|

Phyton Biotech’s Plant Cell Fermentation (PCF) technology has been successfully used to develop high-yielding plant cell lines of the source of cyclopamine, a key raw material for PellePharm’s patedigib topical gel.

AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation

By |2019-04-18T21:06:38+00:00April 18th, 2019|

AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines.

Go to Top